Clinical Trials Logo

Clinical Trial Summary

This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04924192
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Yongsheng Li, Doctor
Phone 18980602258
Email wangys@wchscu.cn
Status Recruiting
Phase Phase 2
Start date August 18, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03776253 - Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer N/A
Recruiting NCT06343402 - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Phase 1
Recruiting NCT05886439 - LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Phase 1
Not yet recruiting NCT06374160 - Exercise in Patients With Advanced Non-small Cell Lung Cancer N/A
Active, not recruiting NCT04819997 - A Nurse-Led Intervention for Fear of Progression in Advanced Cancer N/A
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Active, not recruiting NCT04785287 - Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Phase 1/Phase 2
Completed NCT05342571 - A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer N/A
Completed NCT04229381 - Resiliency Among Older Adults Receiving Lung Cancer Treatment N/A
Active, not recruiting NCT05640765 - BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers N/A
Not yet recruiting NCT04702009 - Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT03707938 - Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Phase 1
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2